We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last
Read MoreHide Full Article
Key Takeaways
CNMD shares gained 16% in a month as organic growth, profitability and the earnings outlook improved.
CONMED raised 2026 EPS guidance to $4.48-$4.60 as adjusted EBITDA margin climbed to 22.7%.
CNMD faces softer AirSeal growth, weak domestic orthopedics and higher working-capital and interest costs.
CONMED Corporation (CNMD - Free Report) shares have gained 16% in the past month, putting the durability of the move in focus. The rally follows better underlying growth, improved profitability and a higher earnings outlook.
Investors still have reasons to stay measured. AirSeal growth has lagged expectations, domestic orthopedics remains soft and higher working-capital and interest costs could limit near-term financial flexibility.
Image Source: Zacks Investment Research
CNMD’s Core Platforms Build Operating Momentum
Second-quarter revenues were $343.5 million, up 0.3% year over year. Excluding gastroenterology products tied to strategic exits, organic constant-currency revenues rose 6%, with international organic constant-currency growth reaching 9.9%.
AirSeal and Buffalo Filter supported General Surgery, while BioBrace contributed to Orthopedic Surgery growth. Stryker Corporation (SYK - Free Report) , which operates across MedSurg and Orthopaedics, is a relevant peer as investors compare execution across surgical-device markets. Medtronic plc (MDT - Free Report) , whose portfolio includes surgical robotics and surgical tools, provides another reference point for the broader procedural-technology backdrop.
CONMED’s Margin Gains Strengthen the Earnings Case
Reported gross margin expanded to 57.5% from 55% a year earlier. An $8.5 million tariff refund aided the quarter, but gross margin still improved 50 basis points excluding that benefit, indicating that mix, foreign exchange and operating execution also helped.
Adjusted EBITDA increased to $78.1 million and adjusted EBITDA margin improved to 22.7% from 20%. CONMED also raised its 2026 earnings guidance to $4.48-$4.60 per share from $4.30-$4.45, strengthening the earnings side of the recent stock move.
AirSeal sales improved sequentially and increased across both capital and single-use products, but growth remained below management’s expectations. CONMED expects improvement in the second half of 2026, though at a slower rate than previously assumed.
Direct smoke evacuation sales exceeded the company’s long-term high-single-digit to low-double-digit growth expectation, but original equipment manufacturer smoke demand declined modestly. Domestic orthopedic sales were nearly flat, even as international orthopedic revenues advanced 10.8% at constant currency.
CONMED’s Cash Flow Risks Could Test the Rally
Cash generation is a weaker part of the setup. Net cash provided by operating activities totaled $50.6 million for the first half of 2026, down from $70.7 million a year earlier, as inventory and working-capital requirements absorbed cash.
Management increased expected 2026 adjusted interest expense to about $33 million from $25-$27 million and lowered free cash flow guidance to about $115 million from roughly $125 million. Those pressures leave less room for execution slippage while CONMED continues funding growth initiatives.
CNMD’s Signals Point to a More Balanced Setup
The 16% monthly advance is supported by better organic growth, margin progress and higher earnings guidance, but the operating picture is not uniformly strong. AirSeal’s slower-than-expected pace, uneven domestic demand and softer cash conversion argue against treating the rally as a one-way signal.
CNMD currently carries a Zacks Rank #3 (Hold), along with a Value Score of A, Growth Score of C, Momentum Score of C and VGM Score of B. The Value Score points to relative valuation appeal, while the C grades for Growth and Momentum are more neutral. Likewise, Stryker and Medtronic also carry a Zacks Rank of 3. CNMD’s VGM Score of B is favorable on a blended basis, but with a Zacks Rank #3, the overall setup remains balanced rather than decisively bullish. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
View the Zacks #1 Rank List
Image: Bigstock
CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last
Key Takeaways
CONMED Corporation (CNMD - Free Report) shares have gained 16% in the past month, putting the durability of the move in focus. The rally follows better underlying growth, improved profitability and a higher earnings outlook.
Investors still have reasons to stay measured. AirSeal growth has lagged expectations, domestic orthopedics remains soft and higher working-capital and interest costs could limit near-term financial flexibility.
Image Source: Zacks Investment Research
CNMD’s Core Platforms Build Operating Momentum
Second-quarter revenues were $343.5 million, up 0.3% year over year. Excluding gastroenterology products tied to strategic exits, organic constant-currency revenues rose 6%, with international organic constant-currency growth reaching 9.9%.
AirSeal and Buffalo Filter supported General Surgery, while BioBrace contributed to Orthopedic Surgery growth. Stryker Corporation (SYK - Free Report) , which operates across MedSurg and Orthopaedics, is a relevant peer as investors compare execution across surgical-device markets. Medtronic plc (MDT - Free Report) , whose portfolio includes surgical robotics and surgical tools, provides another reference point for the broader procedural-technology backdrop.
CONMED’s Margin Gains Strengthen the Earnings Case
Reported gross margin expanded to 57.5% from 55% a year earlier. An $8.5 million tariff refund aided the quarter, but gross margin still improved 50 basis points excluding that benefit, indicating that mix, foreign exchange and operating execution also helped.
Adjusted EBITDA increased to $78.1 million and adjusted EBITDA margin improved to 22.7% from 20%. CONMED also raised its 2026 earnings guidance to $4.48-$4.60 per share from $4.30-$4.45, strengthening the earnings side of the recent stock move.
CONMED Corporation EPS Diluted (Quarterly)
CONMED Corporation eps-diluted | CONMED Corporation Quote
CNMD Still Faces Uneven Growth Signals
AirSeal sales improved sequentially and increased across both capital and single-use products, but growth remained below management’s expectations. CONMED expects improvement in the second half of 2026, though at a slower rate than previously assumed.
Direct smoke evacuation sales exceeded the company’s long-term high-single-digit to low-double-digit growth expectation, but original equipment manufacturer smoke demand declined modestly. Domestic orthopedic sales were nearly flat, even as international orthopedic revenues advanced 10.8% at constant currency.
CONMED’s Cash Flow Risks Could Test the Rally
Cash generation is a weaker part of the setup. Net cash provided by operating activities totaled $50.6 million for the first half of 2026, down from $70.7 million a year earlier, as inventory and working-capital requirements absorbed cash.
Management increased expected 2026 adjusted interest expense to about $33 million from $25-$27 million and lowered free cash flow guidance to about $115 million from roughly $125 million. Those pressures leave less room for execution slippage while CONMED continues funding growth initiatives.
CNMD’s Signals Point to a More Balanced Setup
The 16% monthly advance is supported by better organic growth, margin progress and higher earnings guidance, but the operating picture is not uniformly strong. AirSeal’s slower-than-expected pace, uneven domestic demand and softer cash conversion argue against treating the rally as a one-way signal.
CNMD currently carries a Zacks Rank #3 (Hold), along with a Value Score of A, Growth Score of C, Momentum Score of C and VGM Score of B. The Value Score points to relative valuation appeal, while the C grades for Growth and Momentum are more neutral. Likewise, Stryker and Medtronic also carry a Zacks Rank of 3. CNMD’s VGM Score of B is favorable on a blended basis, but with a Zacks Rank #3, the overall setup remains balanced rather than decisively bullish. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.